Preoperative Gabapentin Versus Bisoprolol for Hemodynamic Optimization During Sinus Surgery

NCT ID: NCT03850093

Last Updated: 2020-02-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-08-31
• Study Completion Date: 2016-12-31

Brief Summary

the current study hypothesized that Gabapentin can be effective as Bisoprolol in reduction of intraoperative bleeding, improving the operative's field visibility and increase the surgeon satisfaction via optimization of blood pressure and heart rate .

A prospective randomized double blinded controlled study. Eligible patients were randomized according to random list generated software and allocated into 3 equal and matched groups (15 patients in each group):-

• Group G: gabapentin group in which Patients were premedicated with oral gabapentin 1200 mg (Conventin 400mg; Evapharm) with sips of water, 2 hours before induction of anesthesia.
• Group B: bisoprolol group in which Patients were premedicated with oral bisoprolol 2.5 mg ( Concor 2.5mg ; Merck/Amoun ) with sips of water, 2 hours before induction of anesthesia.
• Group C: control group in which Patients were premedicated with oral placebo with sips of water, 2 hours before induction of anesthesia.

Detailed Description

Hypothesis:

Gabapentin can be effective as Bisoprolol in reduction of intraoperative bleeding, improving the operative's field visibility and increase the surgeon satisfaction via optimization of blood pressure and heart rate.

Objectives Compare the effect of preoperative Gabapentin with Bisoprolol on hemodynamics, surgical field optimization during endoscopic nasal surgeries.

Technical design:

A) Site of study :

The study was conducted at Anesthesia and Surgical intensive care and Otorhinolaryngology departments, faculty of medicine, Zagazig University.

B) Sample Size :

According to 80% power of the study, 95% CI and calculated volume of blood loss 200±40 ml and 150±55ml on Gabapentin (22) and Bisoprolol (15) premedication respectively, the estimated Sample size was 54 patients (open EPI) , 63 patients were included in the study to compensate for drop out.

Randomization was carried out on 63 patients to compensate for drop out . All planned ESS procedures was managed by the same anesthetist and surgeon who were blinded to the used study's premedication. The surgeon was blinded to the monitor recording the hemodynamic variables.

All patients had been preoperatively evaluated according to standard local protocol. Preoperative surgical preparation and proper management of infection were confirmed to every patient.

Patient was premedicated by IV ranitidine 50 mg, midazolam 0.05 mg/kg and atropine 20µg/kg immediately before admission to the operating room.

On admission to the operating room, Standard monitoring included 5 leads ECG, non-invasive blood pressure, Pulse Oximetry and End-tidal carbon dioxide (ETCO2) trace were applied (B40i Monitor - GE Healthcare, Finland).

Anesthesia was induced with IV propofol 2 mg/kg and fentanyl 1 µg/kg was given for analgesia. Cisatracurium 0.15 mg/kg IV was given to facilitate direct laryngoscopy and orotracheal intubation. The patient was ventilated at tidal volume 6-8mL/kg and respiratory rate that achieved ETCO2 of 30-35 mmHg. Oropharyngeal pack was inserted.

Anesthesia was maintained by isoflurane based on MAC 1.2 % until a steady state of anesthesia was achieved (defined as a state of anesthesia when no changes in hemodynamic variables take place for at least 10 min). An increase of ≥ 20% of basal value in both HR and MAP was treated with increasing the concentration of isoflurane by 0.5% and increments of fentanyl 1 μg/kg. Muscle relaxation was confirmed by cisatracurium 0.03mg/kg every 20 mins. IV lactated ringer solution was infused at approximately 6ml/kg/hr till the end of the procedure.

All patients were positioned supine and the bed-head of the surgical table was raised by 30° to improve venous drainage.

Before the beginning of surgical procedure, well wrung out cotton pledgets soaked with 4 ml of 2% lignocaine with 1:200,000 adrenaline were topically applied to the nasal mucous membrane for 10 min (no infiltration).

Technique for hemodynamic optimization:

Target mean arterial pressure (MAP) was 60-70 mmHg during the surgical procedure to achieve Fromm and Boezaart category scale of 2 or 3 which is judged to be optimal for surgery (20).

If the MAP was still ˃70mmHg in spite of increasing isoflurane inhalation to 2.5%, nitroglycerine (1-10 μg/kg/min.) titrated to effect.

If the heart rate was more than 100 beats/ minute, propranolol was titrated 1-3 mg/hour to achieve target MAP.

If mean arterial pressure (MAP) decreased to less than 60 mm Hg, ephedrine in increments of 3 mg was given.

Withdrawal vasoactive agents:

After recording the surgeons' opinion regarding the surgical field and about 15 minutes before ending surgery, the infusion of any vasoactive medication (if used) was stopped and the anesthetic agent was decreased allowing HR and MAP to return to their basal value. If Hypotension (defined as SAP< 90mmHg and bradycardia less than 60 bpm) persisted, they was treated by ephedrine in increments of 3 mg .

On compilation of surgical procedure, anesthesia was discontinued and reversal of neuromuscular blockade was achieved using IV neostigmine 0.08 mg/kg and atropine 20µg/kg. After removal of oropharyngeal pack, oropharyngeal suction was performed. On the start of obeying commands, patients were extubated and shifted to recovery room.

Patients were discharged to the ward after reaching a score ≥ 9 on the Modified Aldrete Scoring System.

During postoperative period up to 6 hours, the patient was monitored for conscious level, oxygen saturation, heart rate and mean arterial blood pressure.

On ward admission, IM diclofenac sodium 75mg was given then every 12 hours. If the patient complained moderate to severe pain (VAS≥ 4) meperidine 25mg increments up to pain relief (maximum 100mg as a single dose) was given.

Conditions

Blood Pressure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

gabapentin

gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative

Group Type: ACTIVE_COMPARATOR

Gabapentin1200 mg

Intervention Type: DRUG

patients received 1200mg gabapentin 2 hrs preoperative

bisoprolol

bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative

Group Type: ACTIVE_COMPARATOR

bisoprolol 2.5mg

Intervention Type: DRUG

patients received 2.5mg bisoprolol 2 hrs preoperative

control

placebo was given to patients of control group 2 hours preoperative

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

patients received oral placebo 2 hrs preoperative

Interventions

Gabapentin1200 mg

patients received 1200mg gabapentin 2 hrs preoperative

Intervention Type: DRUG

bisoprolol 2.5mg

patients received 2.5mg bisoprolol 2 hrs preoperative

Intervention Type: DRUG

placebo

patients received oral placebo 2 hrs preoperative

Intervention Type: DRUG

Other Intervention Names

gaptin; concor; vitamins

Eligibility Criteria

Inclusion Criteria

• patients who underwent functional endoscopic sinus surgery
• ability to swallow tablets

Exclusion Criteria

• suspected difficult airway
• basal HR <60/min.
• chronic cardiovascular or cerebrovascular disease
• bronchial asthma or COPD
• DM
• bleeding disorders
• anemia (Hb level< 10 gm/dl)
• renal or hepatic insufficiency
• psychiatric disorders
• chronic treatment by BBs, gabapentin or drugs that affect coagulation
• acute nasal infection
• allergy/contraindications to any of the study's drugs.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zagazig University

OTHER_GOV

Sponsor Role: lead

Responsible Party

abeer M. elnakera

assistant professor of anesthesia and surgical intensive care

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Abeer M. Elnakera, doctorate

Role: PRINCIPAL_INVESTIGATOR

faculty of medicine - Zagazig university

Ayman A. Hassan, doctorate

Role: STUDY_CHAIR

Zagazig University

Maram wagdy, Master

Role: STUDY_CHAIR

Zagazig University

Mohamed W. El-Anwar, doctorate

Role: STUDY_CHAIR

Zagazig University

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

ZU-IRB 2139-24-5-2015

Identifier Type: -

Identifier Source: org_study_id